Involvement of the cannabinoid CB1 receptor in the opioid inhibition of the response to cholecystokinin and acute withdrawal response

被引:6
|
作者
Romanelli, L
Palmery, M
Tucci, P
Amico, MC
Morrone, LA
Valeri, P
机构
[1] Univ Roma La Sapienza, Dipartimento Fisiol Umana & Farmacol Vittorio Ers, I-00185 Rome, Italy
[2] Univ Calabria, Dipartimento Farmacobiol, Arcavacata Di Rende, Rende, Italy
关键词
opioid; cannabinoid; acute withdrawal; SR141716; WIN 55,212-2;
D O I
10.1016/j.neuro.2005.03.010
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Numerous recent studies have reported major functional interactions between cannabinoid and opioid systems. These interactions can be studied in the myenteric plexus-longitudinal muscle isolated preparations. We had previously shown that in the guinea-pig ileum (GPI), the opioid acute withdrawal response is under the inhibitory control of several systems; g-opioid agonist exposure indirectly activates the kappa-opioid system; conversely, exposure to a kappa-opioid agonist indirectly activates the A-system; the indirectly activated opioid system inhibits the withdrawal response. The adenosine A(1) system is also indirectly activated by opioids and it inhibits the withdrawal response. We had also shown that indirect activation is prevented or antagonized by cholecystokinin (CCK-8). In GPI preparations briefly exposed to the mu-agonist, dermorphine (DERM) and then challenged with naloxone (NL), the cannabinoid CB1 antagonist, SR141716 (SR), increased the withdrawal responses to NL, but only did so in presence of a kappa-opioid and an adenosine A(1) antagonist. Under similar experimental conditions, SR also enhances the kappa-Opioid withdrawal response. In opioid agonist/CCK-8/NL tests, SR antagonized the inhibition of the tissue response to CCK-8 induced by the mu- or kappa-opioid agonist and increased the kappa-withdrawal response, but not the mu-withdrawal response. However the dose-response curve against dermorphine inhibition of the response to CCK-8 was bell-shaped and the highest SR concentration also significantly decreased the mu-withdrawal response. In preparations exposed to dermorphine or to the kappa-agonist, U-50,488H, the cannabinoid agonist WIN 55,212-2 increased the opioid-induced inhibition of the tissue response to CCK-8 and decreased the NL-induced responses. These results show that opioid exposure may also activate the cannabinoid CB1 system, which leads to all inhibition Of the opioid acute withdrawal response. This phenomenon and the antagonistic effect of SR on the opioid-induced inhibition of the response to CCK-8 suggest that reciprocal interaction between opioid and cannabinoid systems are operating in the enteric nervous system. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:819 / 827
页数:9
相关论文
共 50 条
  • [1] μ opioid and CB1 cannabinoid receptor interactions:: reciprocal inhibition of receptor signaling and neuritogenesis
    Rios, Carl
    Gomes, Ivone
    Devi, Lakshmi A.
    BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (04) : 387 - 395
  • [2] Receptor dimerization of the μ-opioid and cannabinoid CB1 receptors
    Uezono, Y
    Matsumoto, M
    Kanaide, M
    Hojo, M
    Sumikawa, K
    Taniyama, K
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 134P - 134P
  • [3] Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat
    Barbara Malinowska
    Grzegorz Godlewski
    Bernard Bucher
    E. Schlicker
    Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356 : 197 - 202
  • [4] Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat
    Malinowska, B
    Godlewski, G
    Bucher, B
    Schlicker, E
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 356 (02) : 197 - 202
  • [5] Involvement of cannabinoid (CB1)-receptors in the development and maintenance of opioid tolerance
    Trang, T.
    Sutak, M.
    Jhamandas, K.
    NEUROSCIENCE, 2007, 146 (03) : 1275 - 1288
  • [6] Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition
    Orio, L.
    Crespo, I.
    Lopez-Moreno, J. A.
    Reyes-Cabello, C.
    Rodriguez de Fonseca, F.
    Gomez de Heras, R.
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2011, 98 (02) : 220 - 226
  • [7] Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice
    Fride, E
    Suris, R
    Weidenfeld, J
    Mechoulam, R
    BEHAVIOURAL PHARMACOLOGY, 2005, 16 (5-6): : 431 - 440
  • [8] Acute regulation of lipolysis by CB1 cannabinoid receptor antagonism
    Wilbur, Kelly
    Briere, Daniel A.
    Keding, Stacy J.
    Michael, M. D.
    Sloop, Kyle W.
    DIABETES, 2007, 56 : A351 - A351
  • [9] The CB1 cannabinoid receptor in the brain
    Howlett, AC
    NEUROBIOLOGY OF DISEASE, 1998, 5 (06) : 405 - 416
  • [10] Cannabinoid CB1 Receptor Antagonists
    Thomas, Brian F.
    DRUG DEVELOPMENT RESEARCH, 2009, 70 (08) : 525 - 526